Antiprotease strategy in pancreatic cancer treatment: Emergence from a preclinical study

Pancreas

Volumn 43, Issue 1, 2014, Pages 53-63

  Brandi, Giovanni ^a   Tavolari, Simona ^a   Guarnieri, Tiziana ^a   Di Marco, Mariacristina ^a   Paterini, Paola ^a   Macchini, Marina ^a   Di Girolamo, Stefania ^a   Papi, Alessio ^a   De Rosa, Francesco ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

gabexate mesilate; gemcitabine; NF B; pancreatic cancer; tumor resistance

Indexed keywords

GABEXATE MESILATE; GELATINASE A; GELATINASE B; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN KINASE B; PROTEINASE INHIBITOR; TENSIN; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL FRACTIONATION; CELL GROWTH; CELL GROWTH ASSAY; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GABEXATE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE PROTEINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891561302     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182a6486e     Document Type: Article

References (38)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
3. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, et al. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35: 335-339.
4. Renouf D, Moore M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther. 2010;10:529-540.
5. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163-172.
6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. (Pubitemid 46972777)
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817-1825.
8. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-3251. (Pubitemid 36712936)
9. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119-127. (Pubitemid 29045184)
10. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9: 346-354. (Pubitemid 36109751)
11. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas. 2008;36:225-235. (Pubitemid 351440925)
12. Yokota T, Yamada Y, Takahashi M, et al. Successful treatment of DIC with a serine proteinase inhibitor. Am J Emerg Med. 2001;19:334-335. (Pubitemid 32642180)
13. Seta T, Noguchi Y, Shimada T, et al. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:1287-1293. (Pubitemid 39627527)
14. Seta T, Noguchi Y. Protease inhibitors for preventing complications associated with ERCP: an update meta-analysis. Gastrointest Endosc. 2011;73:700-706.
15. Takahashi H, Funahashi H, Sawai H, et al. Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alphaYmediated apoptosis in human pancreatic cancer cells. Dig Dis Sci. 2007;52:2646-2652. (Pubitemid 47373891)
16. Ohta N, Yotsuyanagi T, Ikeda K. Degradation of gabexate mesilate catalyzed by human serum albumin. Int J Pharm. 1986;29:137-146. (Pubitemid 16102005)
17. Nishijima MK, Takezawa J, Taenaka N, et al. Application of HPLC measurement of plasma concentration of gabexate mesilate. Thromb Res. 1983;31:279-284. (Pubitemid 13023145)
18. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2¶,2¶-difluorodeoxycytidine 5¶-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27:258-262.
19. Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist. 2008;13:261-276. (Pubitemid 351679901)
20. Albini A, Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc. 2007;2:504-511. (Pubitemid 47040014)
21. Soares R, Balogh G, Guo S, et al. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol. 2004;18:2333-2343. (Pubitemid 39215261)
22. Gilmore TD. Introduction to NF-JB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684. (Pubitemid 44657845)
23. Basseres DS, Baldwin AS. Nuclear factor-JB and inhibitor of IKB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817-6830. (Pubitemid 44657854)
24. Hayden MS, Ghosh S. Signaling to NF-JB. Genes Dev. 2004;18: 2195-2224.
25. Asano T, Yao Y, Zhu J, et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant PTEN expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004;23:8571-8580. (Pubitemid 39576463)
26. Kim HS, Kim GY, Lim SJ, et al. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology. 2010;42:655-660.
27. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-kappa B activity by Ikappa B alpha M suppresses tumorigenesis. Oncogene. 2003;22:1365-1370. (Pubitemid 36384598)
28. Xiong HQ, Abbruzzese JL, Lin E, et al. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 2004;108:181-188. (Pubitemid 37541768)
29. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer. 2001;92:361-369. (Pubitemid 32249712)
30. Matsuo Y, Ochi N, Sawai H, et al. CXCL8/IL-8 and CXCL12/ SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 2009;124:853-861.
31. Gong YL, Xu GM, Huang WD, et al. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol. 2000;73:95-99. (Pubitemid 30123732)
32. Nagakawa Y, Aoki T, Kasuya K, et al. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas. 2002;24:169-178. (Pubitemid 34171293)
33. Bloomston M, Zervos EE, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002;9:668-674. (Pubitemid 34857984)
34. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003;2:14.
35. Ko AH, Youssoufian H, Gurtler J, et al. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2011;30:1597-1006.
36. Basseres DS, Baldwin AS. Nuclear factor-JB and inhibitor of IKB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817-6830. (Pubitemid 44657854)
37. Tang H, Park S, Sun SC, et al. RKIP inhibits NF-kappaB in cancer cells by regulating upstream signalling components of the IkappaB kinase complex. FEBS Lett. 2010;584:662-668.
38. Takano S, Sogawa K, Yoshitomi H, et al. Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer. 2010;103:223-231.